日搏

日搏

English   |    | 加入收藏   |  站点导航
当前位置:首页>日搏>学术报告
随机复杂结构与数据科学重点实验室
学术报告


浏览次数:

 
Speaker:

Dr.Peng Jiang,Earl Stadtman Investigator National Cancer Institute National Institute of Health, Bethesda, MD, USA

Inviter: 张世华 研究员
Title:
Big-data Approaches to Model Cancer Therapy Response and Resistance
Time & Venue:

2019.5.23 10:00 S813

Abstract:

The rapid growth of big-data resources, catalyzed by breakthroughs in genomics technologies, has resulted in a paradigm shift in cancer research. I will introduce my recent works that integrated the vast amount of public data to model the cancer therapy efficacy. To predict immunotherapy response, we developed TIDE, a computational method to model two primary mechanisms of tumor immune evasion: the induction of T cell dysfunction in immune-hot tumors and the prevention of T cell infiltration in immune-cold tumors [1]. TIDE repurposed many clinical data cohorts without immunotherapy to identify immune evasion signatures as surrogate immunotherapy biomarkers. Using pre-treatment RNA-Seq or NanoString tumor expression profiles, TIDE predicted the outcome of melanoma patients treated with first-line anti-PD1 or anti-CTLA4 more accurately than other biomarkers. TIDE also revealed new immunotherapy resistance regulators, such as SERPINB9, which hijacked the self-protection strategy of T cells for tumor immune evasion. Besides the immunotherapy focus, we also developed CARE, a computational method focused on targeted therapies, to identify synergistic drug combinations to overcome the resistance to primary treatments, using cell line compound screens [2]. In summary, my recent works demonstrated that the integration of big public data is a cost-effective approach to rediscover new therapeutic knowledge [3].

Affiliation:  

学术报告中国科学院数学与系统科学研究院日搏官网

日搏

地址 北京市海淀区中关村东路55号 思源楼6-7层 南楼5-6、8层 100190
?2000-2013 京ICP备05058656号